Unstable molecular structures lead to rapid degradation and loss of biological activity. Enhancing structural integrity through mediated bonding extends shelf life and therapeutic efficacy.

Restricted protospacer adjacent motif recognition and suboptimal delivery vehicle stability limit therapeutic efficacy. Enhancing specificity and payload integrity prevents off-target mutations and low protein expression.

The inability of the immune system to recognize and attack endogenous proteins or tumor antigens. Overcoming this biological barrier is necessary for effective cancer immunotherapy and autoimmune disease treatment.